ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Meredith Cook also recently made the following trade(s):
- On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.54, for a total transaction of $23,816.00.
- On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $53.92, for a total value of $21,568.00.
ANI Pharmaceuticals Stock Up 1.7 %
ANIP stock opened at $62.49 on Monday. The stock has a market cap of $1.36 billion, a P/E ratio of -113.62 and a beta of 0.62. The stock’s fifty day simple moving average is $58.40 and its two-hundred day simple moving average is $58.06. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81.
Institutional Inflows and Outflows
Analysts Set New Price Targets
ANIP has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Guggenheim increased their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $80.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $79.75.
Get Our Latest Research Report on ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Articles
- Five stocks we like better than ANI Pharmaceuticals
- Earnings Per Share Calculator: How to Calculate EPS
- How to Build the Ultimate Everything ETF Portfolio
- Technology Stocks Explained: Here’s What to Know About Tech
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Splits, Do They Really Impact Investors?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.